ARQL News and Press, ArQule Inc. From 12/02/19

This has been a banner year for three biotech stocks and their shareholders. All of them have soared in response to promising clinical trial results for some very different experimental therapies. If you're not sure why these stocks are among the biotech industry's top performers, let's review ...

Conference call and webcast with ArQule management to be held on Monday, December 9, 2019 at 8:15 a.m. EST ArQule management to hold an Investor Event on Monday, December 9, 2019 from 8:00-10:00 p.m. EST in Orlando, FL ArQule, Inc. (Nasdaq: ARQL) today announced that final clinica...

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2019 in London, UK. About ArQule ArQule is a biopharmaceutical company engaged in the research and developmen...

This article takes a look at the best-performing small-cap stocks with a list that presents an interesting group of emerging companies that are fast-growing or have attracted significant bullish sentiment based on a strong outlook. We take the Russell 2000 ( IWM ) constituents as our univers...

Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...

Shares of ArQule (NASDAQ: ARQL) fell over 28% today after the company released an abstract to be presented at an upcoming scientific conference. The abstract includes interim results from an ongoing phase 1 clinical trial for its lead drug candidate, ARQ 531, in patients with cancers affecti...

ArQule ( ARQL -17.2% ) slumps on increased volume in early trade in apparent response to a just-released abstract on blood cancer candidate ARQ 531, a reversible BTK inhibitor, that will be presented at ASH next month. More news on: ArQule, Inc., Eli Lilly and Company, Healthcare stock...

ARQ 531 demonstrates substantial anti-tumor activity in refractory CLL patients and manageable safety profile A total of 10 patients experienced partial responses (PRs) as of July 19 th , the cutoff date for data included in the abstract, primarily at the higher doses: 7 with CLL/SL...

ArQule ( ARQL ) announced that it had dosed the first patient in the registrational study known as MOSAIC. This study will be tasked with exploring the drug miransertib in treating patients with PIK3CA-related Overgrowth Spectrum disorders (PROS). The move to start the registration stu...

Image source: The Motley Fool. Arqule Inc   (NASDAQ: ARQL) Q3 2019 Earnings Call Oct 30, 2019 , 9:00 a.m. ET Operator Continue reading